Cover Image
市場調查報告書

骨髓性白血病細胞分化誘導蛋白質Mcl-1:開發中產品分析

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364853
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
骨髓性白血病細胞分化誘導蛋白質Mcl-1:開發中產品分析 Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 60 Pages
簡介

本報告提供以骨髓性白血病細胞分化誘導蛋白質Mcl-1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

骨髓性白血病細胞分化誘導蛋白質Mcl-1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AbbVie Inc.
  • Complix NV
  • Les Laboratoires Servier SAS
  • Princeton University
  • 武田藥品工業

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0142TDB

Summary

Global Markets Direct's, 'Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Review, H1 2016', provides in depth analysis on Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted pipeline therapeutics.

The report provides comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1)
  • The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) Overview
  • Therapeutics Development
    • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Stage of Development
    • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Therapy Area
    • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Indication
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Companies
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Products under Development by Universities/Institutes
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Complix NV
    • Les Laboratoires Servier SAS
    • Princeton University
    • Takeda Pharmaceutical Company Limited
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Drug Profiles
    • AT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Proteins to Inhibit MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Mcl-1 for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMI-77 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Dormant Projects
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (Bcl-2-Like Protein 3 or Bcl-2-Related Protein EAT/Mcl1) - Featured News & Press Releases
    • Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies
    • Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
    • Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
    • Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
    • Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent
    • Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent
    • Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
    • Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting
    • Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting
    • May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting
    • May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
    • Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer
    • Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory Prostate Cancer
    • Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic Leukemia
    • Jun 05, 2006: Clinical Data On Ascenta Therapeutics Lead Product AT-101 Presented At The 2006 American Society For Clinical Oncology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by AbbVie Inc., H1 2016
  • Pipeline by Complix NV, H1 2016
  • Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Pipeline by Princeton University, H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top